Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 11/20 | 0.67 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3138731 | 1.00 | GRM2 (0.67) | GRM2HRH3KCNH2SMN1; SMN2NPSR1 | |
| SCHEMBL3138336 | 1.00 | GRM2 (0.67) | GRM2HRH3KCNH2SMN1; SMN2NPSR1 | |
| SCHEMBL3133816 | 0.99 | GRM2 (0.68) | GRM2HRH3KCNH2SMN1; SMN2NPSR1 | |
| SCHEMBL3138676 | 0.97 | GRM2 (0.63) | GRM2HRH3KCNH2SMN1; SMN2NPSR1 | |
| SCHEMBL3138692 | 0.97 | GRM2 (0.63) | GRM2HRH3KCNH2SMN1; SMN2NPSR1 | |
| SCHEMBL3134494 | 0.90 | GRM2 (0.66) | GRM2HRH3KCNH2SMN1; SMN2NPSR1 | |
| SCHEMBL1515985 | 0.88 | GRM2 (0.65) | GRM2SMN1; SMN2NPSR1POLBKMT2A | |
| SCHEMBL3138743 | 0.88 | GRM2 (0.65) | GRM2SMN1; SMN2NPSR1POLBKMT2A | |
| SCHEMBL3138739 | 0.88 | GRM2 (0.65) | GRM2SMN1; SMN2NPSR1POLBKMT2A | |
| SCHEMBL3133865 | 0.88 | GRM2 (0.62) | GRM2SMN1; SMN2NPSR1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2137193-B1 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI SA (FR) | 2017-08-09 | — | — | EP | claimed |
| US-8642603-B2 | Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof | SANOFI (FR) | 2014-02-04 | — | — | US | claimed |
| US-20100075994-A1 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI-AVENTIS (FR) | 2010-03-25 | — | — | US | claimed |
| EP-2137193-B1 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI SA (FR) | 2017-08-09 | — | — | EP | disclosed |
| EP-2137193-B1 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI SA (FR) | 2017-08-09 | — | — | EP | disclosed |
| US-8642603-B2 | Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof | SANOFI (FR) | 2014-02-04 | — | — | US | disclosed |
| US-20100075994-A1 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI-AVENTIS (FR) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075994-A1 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | GRM2, GRM1, GRIN2C | GRM2 1/4885HRH3 36/4885KCNH2 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.